KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Tax Provisions (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Tax Provisions for 17 consecutive years, with $582.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 108.08% to $582.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, up 130.4% year-over-year, with the annual reading at $1.9 billion for FY2025, 130.4% up from the prior year.
  • Tax Provisions hit $582.0 million in Q4 2025 for Abbott Laboratories, up from $536.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $582.0 million in Q4 2025 to a low of -$7.2 billion in Q4 2024.
  • Historically, Tax Provisions has averaged -$49.6 million across 5 years, with a median of $299.5 million in 2024.
  • Biggest five-year swings in Tax Provisions: surged 1545.45% in 2021 and later tumbled 3681.59% in 2024.
  • Year by year, Tax Provisions stood at $338.0 million in 2021, then dropped by 15.09% to $287.0 million in 2022, then dropped by 29.97% to $201.0 million in 2023, then crashed by 3681.59% to -$7.2 billion in 2024, then skyrocketed by 108.08% to $582.0 million in 2025.
  • Business Quant data shows Tax Provisions for ABT at $582.0 million in Q4 2025, $536.0 million in Q3 2025, and $371.0 million in Q2 2025.